Sachi Bio Advances Its ADDIS™ Platform—Accelerated Drug Discovery in Space—Aboard NASA’s SpaceX CRS-34
- Jul 1
- 3 min read
Multi-Organ Tissue Models Head to the International Space Station to Accelerate Discovery for Neurological, Cardiac, Metabolic, and Systemic Diseases
ERIE, CO – July 1, 2026 — Sachi Bio, a biotechnology company pioneering RNA-based therapeutics through its proprietary Nanoligomer™ platform, announced the successful completion of an orbital mission that advanced ADDISTM (Accelerated Drug Discovery in Space)—the company’s multi-organ, multi-indication discovery platform. The InSPA–Sachi Nanoligomer investigation launched to the International Space Station (ISS) aboard NASA’s SpaceX CRS-34 commercial resupply mission on May 15, 2026, lifting off from NASA’s Kennedy Space Center in Florida. The flight carried laboratory-grown tissue models of the human brain, heart, liver, and kidney, which were treated in microgravity with Sachi Bio’s novel RNA-based Nanoligomer™ medicines.
ADDIS: A Multi-Organ, Multi-Indication Discovery Platform
Microgravity accelerates the biological processes of aging and disease, compressing changes that unfold over years on Earth into a matter of weeks in orbit. Through ADDIS—Accelerated Drug Discovery in Space—Sachi Bio harnessed this accelerated environment as a testing ground to discover and validate therapeutics faster than conventional methods allowed. Building on previous flights SpaceX-29 & 31, aboard CRS-34, the Sachi Bio extended ADDIS beyond neurodegeneration, applying its programmable Nanoligomer™ platform to tissue models spanning the brain, heart, liver, and kidney to probe conditions across neurology, cardiology, metabolism, oncology, and autoimmunity in a single mission.
A Repeatable Engine for Patient-Focused Discovery
ADDIS was designed to operate as a repeatable drug discovery service rather than a single experiment. By running many organ systems and disease models in parallel within one flight, Sachi Bio compressed the design-build-test-learn cycle and generated validated therapeutic candidates across several indications at once. The platform’s programmable nature means new diseases can be brought into the pipeline without rebuilding the underlying discovery infrastructure—so a promising target for a patient population can move from question to tested candidate in a fraction of the usual time. The result is a standing capability to pursue the diseases that matter most to patients, on demand and at scale.
Building on a Proven Space Heritage
Sachi Bio was the first pharmaceutical company in the world to test RNA therapeutics in space, beginning with its 2023 mission aboard SpaceX CRS-29. In prior ISS investigations, the company’s lead candidates, NI112 and NI113, safely reduced neurodegenerative disease markers in 3D human brain organoids exposed to the space environment. The CRS-34 flight builds directly on that foundation and on the company’s recently awarded NASA InSPA (In Space Production Applications) Phase 2 contract, which is scaling the Nanoligomer™ platform for neurological and systemic diseases.
“This mission proved what ADDIS was built to do. By treating brain, heart, liver, and kidney tissue models side by side in the accelerated environment of space, we identified molecular targets shared between space-induced decline and terrestrial disease across multiple indications at once—turning a single flight into a discovery engine for the patients waiting on new treatments. Every flight sharpens the precision of our Nanoligomer™ technology. ” said Dr. Anushree Chatterjee, Chief Executive Officer and co-founder of Sachi Bio.
From Orbit Back to the Lab
Following its stay aboard the ISS, the experiment returned to Earth in June 2026 aboard the SpaceX Dragon spacecraft, and the treated tissue models are now undergoing analysis at Sachi Bio’s laboratories. Findings from the mission are expected to guide the next generation of Nanoligomer™ candidates and to inform the company’s dual-use strategy: protecting astronaut health on long-duration missions while advancing treatments for patients on Earth.
“Our mission is to build the ultimate biological shield—one that defends the human body against the stresses of deep space and the diseases of aging alike. With ADDIS, we turned that ambition into a multi-organ, multi-indication platform that can take on many diseases at once, so more patients see progress sooner,” said Dr. Prashant Nagpal, Chief Operating Officer and co-founder of Sachi Bio.
Advancing Therapeutics for Earth and Space
Sachi Bio’s Nanoligomer™ platform is a programmable RNA therapeutic discovery engine designed to target conditions including ALS, Alzheimer’s disease, cancer, and metabolic and autoimmune disorders. The company’s work has drawn support from NASA, NIH, National Academy of Medicine, and the U.S. Department of Defense,. Sachi Bio is currently advancing lead candidate NI112 towards clinical studies for chronic neuroinflammation in ALS. Through ADDIS, Sachi Bio combines space-based research with its terrestrial pipeline to translate discoveries made in orbit into transformative treatments for patients and families around the world.
About Sachi Bio
Sachi Bio is a biotechnology company developing RNA-based therapeutics for neurodegenerative diseases, cancer, and aging-related conditions. The company integrates molecular biology, bioinformatics, and space-based research through its proprietary Nanoligomer™ platform—a programmable RNA therapeutic discovery engine—to accelerate drug discovery and molecular innovation. Its ADDIS™ (Accelerated Drug Discovery in Space) platform provides a repeatable, multi-organ, multi-indication engine for discovering therapies across multiple diseases at once.
Media Contact
Sachi Bio
3000 Airport Drive, Unit 201, Erie, CO 80516
720-361-2159 • www.sachibio.com
